<SEC-DOCUMENT>0001628280-23-006039.txt : 20230302
<SEC-HEADER>0001628280-23-006039.hdr.sgml : 20230302
<ACCEPTANCE-DATETIME>20230302160332
ACCESSION NUMBER:		0001628280-23-006039
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230302
ITEM INFORMATION:		Results of Operations and Financial Condition
FILED AS OF DATE:		20230302
DATE AS OF CHANGE:		20230302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARDELYX, INC.
		CENTRAL INDEX KEY:			0001437402
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36485
		FILM NUMBER:		23698790

	BUSINESS ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555
		BUSINESS PHONE:		510-745-7047

	MAIL ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTERYX INC
		DATE OF NAME CHANGE:	20080611
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ardx-20230302.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:0a444791-afe7-49bc-8f51-fffdfc3eca45,g:505b19a8-2c09-477a-9961-e5488b6182f0,d:25868b13bb0544e0b6ee7e47f7d05549--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ardx-20230302</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV80L2ZyYWc6Yzg0OWNjMmU3OTI1NGUzYzkwMDUwODhkODg0ZjRmNzMvdGFibGU6ODA3NzllMTU2MGNiNGFkY2JlNDBkMzgzMzkxNjgxZGYvdGFibGVyYW5nZTo4MDc3OWUxNTYwY2I0YWRjYmU0MGQzODMzOTE2ODFkZl8yLTEtMS0xLTQ2MDE2_9e10fe17-1e88-4c15-9aa0-e692c1ee449d">0001437402</ix:nonNumeric><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV80L2ZyYWc6Yzg0OWNjMmU3OTI1NGUzYzkwMDUwODhkODg0ZjRmNzMvdGFibGU6ODA3NzllMTU2MGNiNGFkY2JlNDBkMzgzMzkxNjgxZGYvdGFibGVyYW5nZTo4MDc3OWUxNTYwY2I0YWRjYmU0MGQzODMzOTE2ODFkZl8zLTEtMS0xLTQ2MDE2_474c86ad-8c73-4dbf-ab91-7164566daf52">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ardx-20230302.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-02</xbrli:startDate><xbrli:endDate>2023-03-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i25868b13bb0544e0b6ee7e47f7d05549_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjU4_b0ad52ce-baf0-4a78-87b8-cc25fa315c6b">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8yMzE_093b37c8-7fa8-4ae4-ad35-ff1c4ba918d4">March 2, 2023</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><img src="ardx-20230302_g1.jpg" alt="ardx-20230302_g1.jpg" style="height:75px;margin-bottom:5pt;vertical-align:text-bottom;width:75px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjU5_524c304c-6714-47a8-acef-e4a781a27b5c">ARDELYX, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6YzU1OGQyZWIxMWY4NDA5OGI5YWJhYjkwNTQzOWVkM2QvdGFibGVyYW5nZTpjNTU4ZDJlYjExZjg0MDk4YjlhYmFiOTA1NDM5ZWQzZF8wLTAtMS0xLTQ2MDE2_5e912e2e-f879-41c4-b08f-6cd2d911c01c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6YzU1OGQyZWIxMWY4NDA5OGI5YWJhYjkwNTQzOWVkM2QvdGFibGVyYW5nZTpjNTU4ZDJlYjExZjg0MDk4YjlhYmFiOTA1NDM5ZWQzZF8wLTEtMS0xLTQ2MDE2_94ce5a34-5f30-4550-86ea-f61d8ca8010d">001-36485</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6YzU1OGQyZWIxMWY4NDA5OGI5YWJhYjkwNTQzOWVkM2QvdGFibGVyYW5nZTpjNTU4ZDJlYjExZjg0MDk4YjlhYmFiOTA1NDM5ZWQzZF8wLTItMS0xLTQ2MDE2_c9d61d90-50fc-441b-86fd-4ecc114e8a9b">26-1303944</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjU1_9bb08b47-290c-4532-9152-5794575f0ae7">400 FIFTH AVE.</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjY0_adc8e764-990e-4b7b-9629-bd5941a2f4c4">SUITE 210</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjU2_5c6bf862-5660-4a4a-ae8a-625997d94f9b">WALTHAM</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjYw_415e29ea-f487-4723-9470-3356101365af">MA</ix:nonNumeric>SSACHUSETTS&#160;<ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjYx_a8c01f1d-e1cc-4f9a-8881-d0a745427857">02451</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including Zip Code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjU3_9e81e431-8f6c-4fee-9b49-1902bc8604b5">510</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjYy_6c875597-f91d-4ae9-be4b-d07083ec0032">745-1700</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:2.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6MGQ5OTY5YjJmNTk2NDdhYzk0MzRkM2I4ZDIzNjJiZjUvdGFibGVyYW5nZTowZDk5NjliMmY1OTY0N2FjOTQzNGQzYjhkMjM2MmJmNV8wLTAtMS0xLTQ2MDE2_aae6df74-68f7-4966-8461-a61c93e5cdb8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6MGQ5OTY5YjJmNTk2NDdhYzk0MzRkM2I4ZDIzNjJiZjUvdGFibGVyYW5nZTowZDk5NjliMmY1OTY0N2FjOTQzNGQzYjhkMjM2MmJmNV8xLTAtMS0xLTQ2MDE2_090cbf4e-c64f-4ca1-91fc-e3ae3e36e013">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6MGQ5OTY5YjJmNTk2NDdhYzk0MzRkM2I4ZDIzNjJiZjUvdGFibGVyYW5nZTowZDk5NjliMmY1OTY0N2FjOTQzNGQzYjhkMjM2MmJmNV8yLTAtMS0xLTQ2MDE2_5257f27b-827c-4c34-bca3-aa31b8301aa2">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6MGQ5OTY5YjJmNTk2NDdhYzk0MzRkM2I4ZDIzNjJiZjUvdGFibGVyYW5nZTowZDk5NjliMmY1OTY0N2FjOTQzNGQzYjhkMjM2MmJmNV8zLTAtMS0xLTQ2MDE2_a9eb5a8a-a1f7-42af-8fc8-2d7756d5c182">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6ODZlMjA2MmE3N2U1NDQ0OWIwY2M2MDY3ZjAyNzM4ZWEvdGFibGVyYW5nZTo4NmUyMDYyYTc3ZTU0NDQ5YjBjYzYwNjdmMDI3MzhlYV8xLTAtMS0xLTQ2MDE2_c3a16731-6c3d-4986-a65f-cde31da60575">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6ODZlMjA2MmE3N2U1NDQ0OWIwY2M2MDY3ZjAyNzM4ZWEvdGFibGVyYW5nZTo4NmUyMDYyYTc3ZTU0NDQ5YjBjYzYwNjdmMDI3MzhlYV8xLTItMS0xLTQ2MDE2_65ccdb1b-141b-4ec9-a83d-9a24f774485b">ARDX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6ODZlMjA2MmE3N2U1NDQ0OWIwY2M2MDY3ZjAyNzM4ZWEvdGFibGVyYW5nZTo4NmUyMDYyYTc3ZTU0NDQ5YjBjYzYwNjdmMDI3MzhlYV8xLTQtMS0xLTQ2MDE2_174bbde9-38fb-4408-9205-df3c79523750">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjYz_5e152cd7-d6d5-4510-80b1-6e57d2b78967">&#9744;</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i25868b13bb0544e0b6ee7e47f7d05549_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-top:12pt;padding-left:58.5pt;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March&#160;2, 2023, Ardelyx, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter and year ended December&#160;31, 2022. The Company also announced that as of February 28, 2023, it had an unaudited cash, cash equivalents and short-term investments balance of $121.0&#160;million. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished under this Item 2.02 shall not be considered &#8220;filed&#8221; under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under&#160;the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered &#8220;filed&#8221; or incorporated by reference therein.</span></div><div id="i25868b13bb0544e0b6ee7e47f7d05549_10"></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:58.5pt;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ardx-20221231xexhibit991.htm">Press release of Ardelyx, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i25868b13bb0544e0b6ee7e47f7d05549_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.618%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 2, 2023</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARDELYX, INC.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Justin Renz</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Justin Renz</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial and Operations Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ardx-20221231xexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idc548b75663e4852b9943de84f1922a9_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:184px"></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;99.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net product sales</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Resubmission of XPHOZAH New Drug Application expected in early-Q2 2023</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Company ends Q4 with approximately $123.9&#160;million in cash and investments</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Conference call scheduled for 4&#58;30 PM Eastern Time</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">WALTHAM, Mass., March&#160;2, 2023 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">- Ardelyx, Inc. (Nasdaq&#58; ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December&#160;31, 2022 and provided a business update. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8220;2022 was a remarkable year for Ardelyx, having met significant milestones that demonstrate our deep and profound commitment to bringing our novel mechanism products to patients in need. In April, we began the process of launching our first therapy, IBSRELA, for adult patients with irritable bowel syndrome with constipation and we are demonstrating significant, quarter-over-quarter prescription growth. In addition, after the positive outcome of our appeal process for XPHOZAH, and a productive Type A meeting with the Food and Drug Administration in February 2023, we believe we are now on the path to launching another important medicine in the second half of the year for patients on dialysis,&#8221; said Mike Raab, president and chief executive officer of Ardelyx. &#8220;Our efforts, our commitment to patients and our tenacity have positioned us well in 2023 as we continue to build growth and momentum for IBSRELA, execute on our plans for a successful launch of XPHOZAH, if approved, and create opportunities to expand our business to support the next phase of the company&#8217;s growth. As evidenced by our continued success with IBSRELA, we are well on our way to realizing our mission to discover, develop and commercialize novel mechanism products for patients with unmet medical needs. We are pleased with our progress and excited about the opportunity to reach even more patients in the future.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Recent Business Highlights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">IBSRELA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> (tenapanor) finishes 2022 with $15.6&#160;million in net product sales, $8.7&#160;million in Q4 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">In March 2022, Ardelyx launched IBSRELA (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in the United States. The targeted commercial launch is focused on high-writing physicians and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">the patients who experience persistent symptoms, despite treatment with a prescription therapy for IBS-C. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Ardelyx has seen consistent month-over-month growth trends in both new and refill prescriptions, supported by data from the independent research firm Spherix which reported in December that 60% of surveyed gastroenterologists had adopted IBSRELA with 32% of non-prescribers intending to adopt within three months. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">XPHOZAH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> (tenapanor) prepares for New Drug Application (NDA) resubmission in early Q2 2023</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">In February, Ardelyx participated in a Type A meeting with members of the U.S. Food and Drug Administration&#8217;s (FDA) Division of Cardiology and Nephrology (DCN) to discuss resubmission of the NDA for XPHOZAH for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The meeting was very productive and provided Ardelyx with information required to complete its NDA resubmission. The company currently intends to submit the NDA early in the second quarter of 2023. Ardelyx is preparing to launch XPHOZAH, if approved, in the second half of 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The resubmission of the NDA follows two significant developments for XPHOZAH that happened in the fourth quarter of 2022, providing a path to bring XPHOZAH to patients following a prolonged appeal process to the Complete Response Letter the company received in July 2021. In November, the Cardiovascular and Renal Drugs Advisory Committee voted nine to four that the benefits of treatment with XPHOZAH outweigh its risks for the control of serum phosphorus in adults with CKD on dialysis when administered as a monotherapy, and voted ten to two, with one abstention, that the benefits of treatment with XPHOZAH in combination with phosphate binder treatment outweigh its risks. Following the favorable outcome of the Advisory Committee meeting, in December, the FDA&#8217;s Office of New Drugs granted the appeal for XPHOZAH and directed the DCN to work with Ardelyx to develop an appropriate label.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other Corporate Developments</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">In February, the company released its first Environmental, Social and Governance (ESG) report, demonstrating the company&#8217;s commitment and progress towards initiatives and best practices that build a more equitable and sustainable society. The report is available on the company&#8217;s website.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">In February, the company reported that it had amended the debt financing agreement with SLR Investment Corp. it entered into in February 2022. The senior term loan facility&#8217;s March 1, 2027 maturity date is unchanged&#59; however the interest only period for the $27.5 million that was drawn at the February 2022 closing may be extended by one year to March 31, 2025 if certain product revenue targets are achieved for the year ended 2023 or the company has received approval by the FDA for the NDA for XPHOZAH on or before November 30, 2023. In addition, the deadline to borrow an additional $22.5 million available under the facility has been extended to December 20, 2023, provided that the company has received approval by the FDA for the NDA for XPHOZAH on or before November 30, 2023 and that the company has achieved certain product revenue targets.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Full Year 2022 Financial Results</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cash Position&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> As of December&#160;31, 2022, the company had total cash, cash equivalents and short-term investments of $123.9&#160;million, as compared to total cash, cash equivalents and short-term investments of $116.7&#160;million as of December&#160;31, 2021. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of February 28, 2023, the company had an unaudited cash, cash equivalents and short-term  investments balance of $121.0&#160;million, which included gross proceeds of $20.0 million for the sale of 7.7 million shares of the company&#8217;s common stock which were sold at a weighted average sales price of approximately $2.60 per share during the period January 1, 2023 to January 12, 2023 under the company&#8217;s sales agreement with Jefferies LLC, dated August 13, 2021, deemed to be &#8220;at-the-market offerings.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">   </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Product Sales&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> Net product sales for IBSRELA were $15.6&#160;million during the year ended December&#160;31, 2022.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%;padding-left:14.5pt">Collaboration Revenue&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> The company generated $36.6&#160;million in collaboration revenue for the year ended December&#160;31, </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><font><br></font></div></div><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">2022, as compared to $10.1&#160;million for the year ended December&#160;31, 2021. The increase in collaboration revenue was primarily the result of $35.0 million in milestone payments and payments under the 2022 amendment to the license agreement between Ardelyx and Kyowa Kirin Co, Ltd (Kyowa Kirin), Ardelyx&#8217;s collaboration partner in Japan, earned upon Kyowa Kirin's submission of a New Drug Application to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis. The company also realized increased product supply revenue in connection with its obligation to supply drug substance to Kyowa Kirin under its license agreement with Kyowa Kirin. Partially offsetting these increases was the full recognition through the end of 2021 of upfront payments associated with the Research Collaboration Agreement entered into with Kyowa Kirin.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">R&#38;D Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#58; Research and development expenses were $35.2&#160;million for the year ended December&#160;31, 2022, a decrease of $55.9&#160;million compared to $91.1&#160;million for the year ended December&#160;31, 2021. Research and development expenses included non-cash stock compensation expense of approximately $3.2&#160;million and $4.1&#160;million in the years ended December&#160;31, 2022, and December&#160;31, 2021, respectively. The decrease in R&#38;D expenses is primarily due to lower clinical study costs as a result of the completion of the OPTIMIZE study, lower tenapanor manufacturing expenses due to the company&#8217;s capitalization of  costs associated with the production of IBSRELA to inventory, and lower expenses for research following the reduction in the research function in the fourth quarter of 2021. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SG&#38;A Expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> Selling, general and administrative expenses were $76.6&#160;million for the year ended December&#160;31, 2022, an increase of $4.3&#160;million compared to $72.3&#160;million for the year ended December&#160;31, 2021. Selling, general and administrative expenses included non-cash stock compensation expense of approximately $7.5&#160;million and $7.9&#160;million in the years ended December&#160;31, 2022, and December&#160;31, 2021, respectively. The increase in selling, general and administrative expenses was primarily due to increased costs associated with the ongoing commercial launch of IBSRELA during 2022.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Net Loss&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Net loss for the year ended December&#160;31, 2022 was $67.2&#160;million, or $(0.42) per share, compared to net loss of $158.2&#160;million, or $(1.52) per share, for the year ended December&#160;31, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:150%">Conference Call Details</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The company will host a conference call today, March&#160;2, 2023, at 4&#58;30 PM ET to discuss today's announcement. To participate in the conference call, please dial (877) 270-2148 (domestic) or (412) 902-6510 (international) and ask to be joined into the Ardelyx call. A webcast of the call can also be accessed by visiting the Investor page of the company's website, www.ardelyx.com, and will be available on the website for 30 days following the call.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">IMPORTANT SAFETY INFORMATION</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">WARNING&#58; RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS</font></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">IBSRELA is contraindicated in patients less than 6 years of age&#59; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.</font></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CONTRAINDICATIONS</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration. </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">WARNINGS AND PRECAUTIONS</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Risk of Serious Dehydration in Pediatric Patients</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old&#59; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years). </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Diarrhea </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">If severe diarrhea occurs, suspend dosing and rehydrate patient.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">MOST COMMON ADVERSE REACTIONS </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The most common adverse reactions in IBSRELA-treated patients (incidence &#8805;2% and greater than placebo) were&#58; diarrhea (16% vs 4% placebo), abdominal distension (3% vs &#60;1%), flatulence (3% vs 1%) and dizziness (2% vs &#60;1%).</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">INDICATION </font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Please see full Prescribing Information, including Boxed Warning, for additional risk information.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:150%">About Ardelyx, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx&#8217;s first approved product, IBSRELA&#174;  (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH&#174;  (tenapanor), a novel product candidate for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and&#47;or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories. For more information, please visit https&#58;&#47;&#47;ardelyx.com&#47; and connect with us on Twitter, LinkedIn and Facebook.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:150%">Forward Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including potential commercial opportunities and other opportunities for the </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt;text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">company, Ardelyx&#8217;s current expectation for both the timing of the NDA submission and potential FDA approval for XPHOZAH, and the potential extension of the interest only period for Ardelyx's senior term loan facility. Such forward-looking statements involve substantial risks and uncertainties that could cause Ardelyx's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties associated with the commercialization of drugs and uncertainties regarding the FDA regulatory process. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March&#160;2, 2023, and its future current and periodic reports to be filed with the Securities and Exchange Commission. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor and Media Contacts&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caitlin Lowie</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clowie&#64;ardelyx.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kimia Keshtbod </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">kkeshtbod&#64;ardelyx.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idc548b75663e4852b9943de84f1922a9_4"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ardelyx,&#160;Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:65.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,140</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,428</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,769</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,261</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,733</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid commercial manufacturing</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,567</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,406</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, current</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,064</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,295</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,752</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,202</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,066</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,913</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 15.4pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 4pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,859</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,277</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,548</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,422</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liability</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,894</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,492</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,711</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,264</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,236</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,727</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,380</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,366</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,855</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,748</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred royalty obligation related to the sale of future royalties</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,254</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,329</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,617</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,066</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,913</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Derived from the audited financial statements included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2021.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="idc548b75663e4852b9943de84f1922a9_7"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-top:10pt;text-align:right"><img alt="image_0.jpg" src="image_0.jpg" style="height:39px;margin-bottom:5pt;vertical-align:text-bottom;width:125px"></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ardelyx,&#160;Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share amounts)</font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:44.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.891%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 2.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,701</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,600</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product supply revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,008</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,031</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,013</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborative development revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,177</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,178</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,158</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,097</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 2.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 4pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,162</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,117</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,142</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,968</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,201</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,140</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,731</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,334</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,599</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,303</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,035&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,302&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,917&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,443&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,143&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,273)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,759)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,346)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(991)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(984)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,400)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,502)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense related to the sale of future royalties</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(832)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,673)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) before provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,695&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,234)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,199)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158,161)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,695</font></td><td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,234)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,207)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158,165)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share - basic and diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.06</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.31)</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.52)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares used in computing net income (loss) per share - basic</font></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,430,121&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,260,610&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,690,083&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,205,645&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares used in computing net income (loss) per share - diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,840,751&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,260,610&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,690,083&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,205,645&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ardx-20230302.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:0a444791-afe7-49bc-8f51-fffdfc3eca45,g:505b19a8-2c09-477a-9961-e5488b6182f0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ardx="http://www.ardelyx.com/20230302" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ardelyx.com/20230302">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20230302_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20230302_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ardelyx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ardx-20230302_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:0a444791-afe7-49bc-8f51-fffdfc3eca45,g:505b19a8-2c09-477a-9961-e5488b6182f0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_62e87265-1cdc-49ad-8d8c-8e4a123222e9_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a492ad38-31bd-4119-9353-8d2501ab3283_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_dbe1fe10-1385-4535-b32d-379c640bdfb4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3d548e71-2719-4d9e-8bd0-b5844d2c0d26_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5d6ddf1c-c494-41d2-8d04-5edce96e3883_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_034972c1-d3a9-45c2-b148-e732c025bc57_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_328d14df-c6e7-4abd-9ad0-8c2d7bd4b4f3_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_ec51ca32-4685-4b2f-8a5e-b55f88b45ce0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_045c21af-60db-42b9-8c73-ed5b76afd221_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2c803ef8-8b37-48e7-8913-ed5d8e31701f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d5ba70c7-55ff-4e51-a822-3e11dbf2f613_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_4929e332-612e-4206-b1f0-98fb544e1a84_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3f6b214a-e4d0-418e-9e4e-43e26de61d79_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8821c084-ab3d-46cc-bd80-f0aac4da7681_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_918cbaf5-561f-4080-a05a-0e776bc1cd93_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_41dd2b62-14d2-4566-9b5d-e892fe89dc25_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1194c26f-dc0d-4f5a-8226-1f8777d62aba_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_848c0f76-028d-4576-aac7-dbe86ef847a8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8977d67d-8c3f-4283-b454-29026682fde7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1f4de982-1adc-4fc1-aa02-f24e2ca9c2c4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b70e7d4b-499e-4c02-892b-91ebf7eed973_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_fd3e87ca-a90f-494c-81f5-ec6ea583f242_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_21fb5ae3-da7f-4fc0-8c9c-7e534d2d54a1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ardx-20230302_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:0a444791-afe7-49bc-8f51-fffdfc3eca45,g:505b19a8-2c09-477a-9961-e5488b6182f0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ardelyx.com/role/Cover" xlink:type="simple" xlink:href="ardx-20230302.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d4ae0f62-346c-4b0b-9c32-b091bdb37e8a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_DocumentType_d4ae0f62-346c-4b0b-9c32-b091bdb37e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2b05e9bf-3eea-4ad5-b5ea-d81a1ddea6e2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_DocumentPeriodEndDate_2b05e9bf-3eea-4ad5-b5ea-d81a1ddea6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_691c7798-4969-41f5-bc1a-8223e3ec7118" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_EntityRegistrantName_691c7798-4969-41f5-bc1a-8223e3ec7118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_48728d72-1395-4300-97b5-bed51ae5db00" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_EntityIncorporationStateCountryCode_48728d72-1395-4300-97b5-bed51ae5db00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0977bdf6-150b-4c66-a40e-7f2bb0fd518b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_EntityFileNumber_0977bdf6-150b-4c66-a40e-7f2bb0fd518b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9a141e08-c16c-4356-a973-772672a12e95" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_EntityTaxIdentificationNumber_9a141e08-c16c-4356-a973-772672a12e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_82bf6bdf-b845-4d2f-a6c8-f4cae90579a2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_EntityAddressAddressLine1_82bf6bdf-b845-4d2f-a6c8-f4cae90579a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_e4e03764-363f-4bdd-b5e9-7e00d8e97803" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_EntityAddressAddressLine2_e4e03764-363f-4bdd-b5e9-7e00d8e97803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b0168e53-0a73-4a54-b91a-ac527177e424" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_EntityAddressCityOrTown_b0168e53-0a73-4a54-b91a-ac527177e424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9506a88c-4b91-4d59-9210-91a7f4c5a9d7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_EntityAddressStateOrProvince_9506a88c-4b91-4d59-9210-91a7f4c5a9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d2a87b37-9fe5-498f-9c97-e3fda0f42e06" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_EntityAddressPostalZipCode_d2a87b37-9fe5-498f-9c97-e3fda0f42e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9c9a29cd-305f-4744-987f-ebc7670a9330" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_CityAreaCode_9c9a29cd-305f-4744-987f-ebc7670a9330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1908fc08-3312-484c-9037-c6337b534493" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_LocalPhoneNumber_1908fc08-3312-484c-9037-c6337b534493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_2d83b054-bf70-46b8-ad9f-3eb05df9f5b3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_WrittenCommunications_2d83b054-bf70-46b8-ad9f-3eb05df9f5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_6f07bcb5-4b74-4a06-aa9d-22e0060e71a8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_SolicitingMaterial_6f07bcb5-4b74-4a06-aa9d-22e0060e71a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_ee83790b-7f4e-4e17-a320-2afc71270423" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_PreCommencementTenderOffer_ee83790b-7f4e-4e17-a320-2afc71270423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_44462f2b-473a-4e9c-a88e-f60a4b2697dc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_44462f2b-473a-4e9c-a88e-f60a4b2697dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f004aeda-5720-45ee-b5ca-6ad18ecb611d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_Security12bTitle_f004aeda-5720-45ee-b5ca-6ad18ecb611d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b1b5b933-a778-438f-90b8-acb25aeb07aa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_TradingSymbol_b1b5b933-a778-438f-90b8-acb25aeb07aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4f39cd22-34c7-4662-9a01-87a210799e26" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_SecurityExchangeName_4f39cd22-34c7-4662-9a01-87a210799e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3c6eaae1-96a8-4fdb-b018-d1e8a071f68b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_EntityEmergingGrowthCompany_3c6eaae1-96a8-4fdb-b018-d1e8a071f68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e077c6e7-63e5-4c7a-b6ce-f2aa34006a46" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_EntityCentralIndexKey_e077c6e7-63e5-4c7a-b6ce-f2aa34006a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1e623e00-de31-4e58-8cde-2b5f07195d38" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d0f8887b-9434-49ec-a94d-e311f1dcb765" xlink:to="loc_dei_AmendmentFlag_1e623e00-de31-4e58-8cde-2b5f07195d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ardx-20230302_g1.jpg
<TEXT>
begin 644 ardx-20230302_g1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !K &L# 2(  A$! Q$!_\0
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%BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R +,# 2(  A$! Q$!_\0
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I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140360535189392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  02,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARDELYX, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1303944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 FIFTH AVE.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">SUITE 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">WALTHAM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">745-1700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARDX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001437402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ardx-20230302_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ardx-20230302.xsd" xlink:type="simple"/>
    <context id="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2023-03-02</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV80L2ZyYWc6Yzg0OWNjMmU3OTI1NGUzYzkwMDUwODhkODg0ZjRmNzMvdGFibGU6ODA3NzllMTU2MGNiNGFkY2JlNDBkMzgzMzkxNjgxZGYvdGFibGVyYW5nZTo4MDc3OWUxNTYwY2I0YWRjYmU0MGQzODMzOTE2ODFkZl8yLTEtMS0xLTQ2MDE2_9e10fe17-1e88-4c15-9aa0-e692c1ee449d">0001437402</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV80L2ZyYWc6Yzg0OWNjMmU3OTI1NGUzYzkwMDUwODhkODg0ZjRmNzMvdGFibGU6ODA3NzllMTU2MGNiNGFkY2JlNDBkMzgzMzkxNjgxZGYvdGFibGVyYW5nZTo4MDc3OWUxNTYwY2I0YWRjYmU0MGQzODMzOTE2ODFkZl8zLTEtMS0xLTQ2MDE2_474c86ad-8c73-4dbf-ab91-7164566daf52">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjU4_b0ad52ce-baf0-4a78-87b8-cc25fa315c6b">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8yMzE_093b37c8-7fa8-4ae4-ad35-ff1c4ba918d4">2023-03-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjU5_524c304c-6714-47a8-acef-e4a781a27b5c">ARDELYX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6YzU1OGQyZWIxMWY4NDA5OGI5YWJhYjkwNTQzOWVkM2QvdGFibGVyYW5nZTpjNTU4ZDJlYjExZjg0MDk4YjlhYmFiOTA1NDM5ZWQzZF8wLTAtMS0xLTQ2MDE2_5e912e2e-f879-41c4-b08f-6cd2d911c01c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6YzU1OGQyZWIxMWY4NDA5OGI5YWJhYjkwNTQzOWVkM2QvdGFibGVyYW5nZTpjNTU4ZDJlYjExZjg0MDk4YjlhYmFiOTA1NDM5ZWQzZF8wLTEtMS0xLTQ2MDE2_94ce5a34-5f30-4550-86ea-f61d8ca8010d">001-36485</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6YzU1OGQyZWIxMWY4NDA5OGI5YWJhYjkwNTQzOWVkM2QvdGFibGVyYW5nZTpjNTU4ZDJlYjExZjg0MDk4YjlhYmFiOTA1NDM5ZWQzZF8wLTItMS0xLTQ2MDE2_c9d61d90-50fc-441b-86fd-4ecc114e8a9b">26-1303944</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjU1_9bb08b47-290c-4532-9152-5794575f0ae7">400 FIFTH AVE.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjY0_adc8e764-990e-4b7b-9629-bd5941a2f4c4">SUITE 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjU2_5c6bf862-5660-4a4a-ae8a-625997d94f9b">WALTHAM</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjYw_415e29ea-f487-4723-9470-3356101365af">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjYx_a8c01f1d-e1cc-4f9a-8881-d0a745427857">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjU3_9e81e431-8f6c-4fee-9b49-1902bc8604b5">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjYy_6c875597-f91d-4ae9-be4b-d07083ec0032">745-1700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6MGQ5OTY5YjJmNTk2NDdhYzk0MzRkM2I4ZDIzNjJiZjUvdGFibGVyYW5nZTowZDk5NjliMmY1OTY0N2FjOTQzNGQzYjhkMjM2MmJmNV8wLTAtMS0xLTQ2MDE2_aae6df74-68f7-4966-8461-a61c93e5cdb8">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6MGQ5OTY5YjJmNTk2NDdhYzk0MzRkM2I4ZDIzNjJiZjUvdGFibGVyYW5nZTowZDk5NjliMmY1OTY0N2FjOTQzNGQzYjhkMjM2MmJmNV8xLTAtMS0xLTQ2MDE2_090cbf4e-c64f-4ca1-91fc-e3ae3e36e013">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6MGQ5OTY5YjJmNTk2NDdhYzk0MzRkM2I4ZDIzNjJiZjUvdGFibGVyYW5nZTowZDk5NjliMmY1OTY0N2FjOTQzNGQzYjhkMjM2MmJmNV8yLTAtMS0xLTQ2MDE2_5257f27b-827c-4c34-bca3-aa31b8301aa2">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6MGQ5OTY5YjJmNTk2NDdhYzk0MzRkM2I4ZDIzNjJiZjUvdGFibGVyYW5nZTowZDk5NjliMmY1OTY0N2FjOTQzNGQzYjhkMjM2MmJmNV8zLTAtMS0xLTQ2MDE2_a9eb5a8a-a1f7-42af-8fc8-2d7756d5c182">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6ODZlMjA2MmE3N2U1NDQ0OWIwY2M2MDY3ZjAyNzM4ZWEvdGFibGVyYW5nZTo4NmUyMDYyYTc3ZTU0NDQ5YjBjYzYwNjdmMDI3MzhlYV8xLTAtMS0xLTQ2MDE2_c3a16731-6c3d-4986-a65f-cde31da60575">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6ODZlMjA2MmE3N2U1NDQ0OWIwY2M2MDY3ZjAyNzM4ZWEvdGFibGVyYW5nZTo4NmUyMDYyYTc3ZTU0NDQ5YjBjYzYwNjdmMDI3MzhlYV8xLTItMS0xLTQ2MDE2_65ccdb1b-141b-4ec9-a83d-9a24f774485b">ARDX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGFibGU6ODZlMjA2MmE3N2U1NDQ0OWIwY2M2MDY3ZjAyNzM4ZWEvdGFibGVyYW5nZTo4NmUyMDYyYTc3ZTU0NDQ5YjBjYzYwNjdmMDI3MzhlYV8xLTQtMS0xLTQ2MDE2_174bbde9-38fb-4408-9205-df3c79523750">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia3692c3ea86540e69020b7ac30670151_D20230302-20230302"
      id="id3VybDovL2RvY3MudjEvZG9jOjI1ODY4YjEzYmIwNTQ0ZTBiNmVlN2U0N2Y3ZDA1NTQ5L3NlYzoyNTg2OGIxM2JiMDU0NGUwYjZlZTdlNDdmN2QwNTU0OV8xL2ZyYWc6NDkxYmJmMGRmNzhiNDRkZThmMTA4OTY5YWY5YTI5NDgvdGV4dHJlZ2lvbjo0OTFiYmYwZGY3OGI0NGRlOGYxMDg5NjlhZjlhMjk0OF8xMjYz_5e152cd7-d6d5-4510-80b1-6e57d2b78967">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
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M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M" !N@&)6EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04
M" !N@&)6)!Z;HJT   #X 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM
M?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(H
MND'8,V2>[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++
M3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$
M%     @ ;H!B5F60>9(9 0  SP,  !,   !;0V]N=&5N=%]4>7!E<UTN>&UL
MK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QX
MWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#
M4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$
MJ+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:
M!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U5
M9"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\
MUDX:?^:+X3]>?P%02P$"% ,4    " !N@&)6!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( &Z 8E;7
MA8-K[0   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( &Z 8E:97)PC$ 8  )PG   3              "  <L!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ;H!B5G(_K(=2!
M"!$  !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( &Z 8E:?H!OPL0(  .(,   -              "  90,
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ ;H!B5I>*NQS     $P(   L
M             ( !< \  %]R96QS+RYR96QS4$L! A0#%     @ ;H!B5JK$
M(A8S 0  (@(   \              ( !61   'AL+W=O<FMB;V]K+GAM;%!+
M 0(4 Q0    ( &Z 8E8D'INBK0   /@!   :              "  ;D1  !X
M;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &Z 8E9ED'F2
M&0$  ,\#   3              "  9X2  !;0V]N=&5N=%]4>7!E<UTN>&UL
64$L%!@     )  D /@(  .@3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ardx-20230302.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ardx-20230302.htm">ardx-20230302.htm</File>
    <File>ardx-20221231xexhibit991.htm</File>
    <File>ardx-20230302.xsd</File>
    <File>ardx-20230302_lab.xml</File>
    <File>ardx-20230302_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ardx-20230302_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ardx-20230302.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ardx-20230302.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ardx-20230302_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ardx-20230302_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ardx-20230302.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ardx",
   "nsuri": "http://www.ardelyx.com/20230302",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230302.htm",
      "contextRef": "ia3692c3ea86540e69020b7ac30670151_D20230302-20230302",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.ardelyx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230302.htm",
      "contextRef": "ia3692c3ea86540e69020b7ac30670151_D20230302-20230302",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-23-006039-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-006039-xbrl.zip
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M@+('%@FGP!>/P#L>.>NX01B50"&P/0 4ZW/'M5$*L:AG1?!/X+,A(-KMP/0
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MW!O6 "L&Z9"<WB5%REQ6,D%.M)0<&5)F?\AE#3P.^U9RC5 0B&Z N\ I^3=
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M14!DDGDK@Q%>CE)82"*<M.P3CP?  DFSG"X,-!1)[$H,*,4EWYC-]Q;0@'M
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M\-B.Z3)$UR_QWC0+_#;)#)H4'6?I@B=\AC.KWU_1O8NJW^V/;RO-TPMV^6V
M9!-N4VC+4J"4/"@>-PY+4;J>3Y1)&B!P17,UKHPL'D96/!DY;*TV74$W(0!:
MQAH"X/O[28U9S%PC8UD:G;@&>&-<\>B'>79E91H..-&[ZO225? >5QQ^#SK^
MO.UH*)>P]!)4&$_%<U)(P@P).8WWEI5KCJQ,\ 1@D-E  )0.'T:Q,X+-AL0O
MJ$@H$7V)G>OQ*)/)\/7F_NK+U;\OY9>:&F_,XH$0XXYE1](@2)>B9L^U]:T!
M51W^UTKF2=<SR[^2)!CY8F*64'@#V'HD A5XE\M*IT>2&2=%3H2_@<[4@ I)
MX_=B?^)!;NJ%D9.[6##%-9CBW2]$QF<I5]R^/7/'X11CUH,T9F3PU\JDGCWR
M:0;9F+%UEF&0_EAK10Y9+5>>8) -<_KQ$@QRJ:VMR2L;Y5H.KVSDU$]OAE=F
M+8%P*91:.8QTK&#.YU;"[PKD,[-9^QGFI7PG>^X:V456@KZLSR*4'&2K'GQ<
MB2?"<'$N0$3WKMZ8TB\TC**^.]++5?-X[,_6)CB"GTQ&;OQ:,W\(HUR;'&)Q
MKK';H=::/MF>X!S;$USPR'*]W:IBFY]"FIBT0RP! ;L8 Q[V5,,%JH+/:S2@
M88!DH@'#?3:]F;[[";T6O@!61%8?\$>1S<E.>/#4G)JJER0#G!TU&XUC9C;T
MDFE4F^S($0 %&.$8Z>NH:@!UM72S5*\9.CNB7!"9LFAYQY+;A@\JZO$?8)*)
MR4F)A\H3@G.6&7J=VR!MQDHI;M_&) BT^-N8O('YJC(5!%.^TZPKF11#%:'=
MZ>K6G](,)XUA6RE+50O#8RE8"/@X^G2BE/J,#@Q &, 93NF4M/ U:*UMV0_=
M ,OI2XKL.O2_TQ<KI?QR\_7V_NSZGMV=?;J\_Y-=77_Z>OOE[/[JZ_62^Y))
M::F#%: <E,A7-0CY^^0_3H$Z!YXU>N_ZM!CZ:*5N5+I>UJ6W-(+E1$XRLWI<
MID<GD3/[K&666WIM[F.];,Q]]M2PU7*SM=BH)[1BN6H 3 A4^O<WE3??)0H%
M5*D:#"(,DKH.0R))'I&;>/*)4BC>FX-OS)AT(.- ,V4T!.27;WU%J/SC[/;Z
MZOH7Y:*XNON-??W$[BYOK[[^?L<N+G_]\^*6*!.HE-U<7ER=W=]>G;,;^.WR
M^OXNI4D%_Q5 &\C%+ M;'2$[A=VI&(5!<9QGQ'CNW,^XZZ?VMHE][!9]SBEQ
M4IJ\&\J: @O4<O2;RW*(U(7M48)O#P1775DW:"-UN<R<Q&IJX4\X9ERRN=@(
M(-=E_XD?N>\"*P7K))PP591S)G7!V!95 SO<BGI4>A/&XPP#9;TXO#=RY,<@
M81^%BUTM>-8LR:X\62_ZC])-&.;$+E0^J=7AD:RQPNP'LK]\U:XE&9G::?@B
M4JF((3)[+#>?!RVC.3G1I@[T2QU;)<_RV<F&S_23<R\)E1.2TD7-[JHUN]O4
M\F1FX]?K^]NSJ^N+JW.2GW?[ZW[(,^Y?$+Y+U "L)RNRCG2LYE+%:ZZ(PTF>
M7J!R5U!)WL '7PPI SZ,0]4]4S4O0F$O.RV@C0P&-.;TBS;\(,,2\^S(G>$B
M2CN_8V?7%^SF]O+\[/=\9K)CZ[Y5Q^=.'9^+\?%!_-UPQ[6BP+79C<)D<:1V
MY4BUN2>&4YQQ<?US(2USOI9*-3IY.OE19C VY!RHRU-E49E(".O%??1==7DF
M+9NZ&:9?3RK6QUH:Y748]AM7N<\JIDU*OK"I:M_1OJ_N:QE?E:#(QWQ3@F :
M).W_9,.9L3L,X @;Y,$T&'(W:#YE0AP7\NH%#I<T\U!S6-O4._.B7I*'-$4?
M^52AL2Z>Q*2B#6DVL6SA56G2^G)Q'L .)QJ;PA-G&GZR1^E4@Y1+)SO0@$*?
M:Y^[+L(N7"L(>MR:USYI1\@QL] DL:V/00U5Y6$YCSP(.7533/,MA@*HPG=$
M'[/Y@ .*&%A."5BPCTP.:(2W14EU<,"NTT #EI>P>>P#=H=UJ!2J&,^<[7UE
MEFL_9(BC%*D+(A(**6\UY2 W6KEU-%ZAL3$)5I(\U)DLQ.YC@*A0]H/%%F92
MZ*2=WW;^/'WY>G?/SK]^^?+UFIU=_._E[=TEN[T\.R=]=N</V?UWSA6QW'GD
MCB$Z6_9VQ2JDIEX[-7\@-';IS4!R2'7RCBG-13KD4U(X,NH_L,>057](7P-F
MW,8SC#:-0XWP*,WXJ$(O_OBVKI\:/\!;'<^*8H\F5\_@9]44Y+__E;U(C\R)
MCW:>F,9^E9VGG+RFEBZ22Z)\YW:XO$H[7/Y,'2[O)CI<GL_I<"G;ZNQK=%26
M;,DH>,A5@O:-:GB(C.]JW(!+4PE3^///XAN \0\K\"GK2/8D3TOXR9.3:=VU
M#QD69]04>>):@9U:]=,=.E$;>*Y+#;1GN-6@/%//(9O/)(W1DL37M*^][&;(
MIH_LA'4VTTR6MG%N^99C3;1G4[O,= O+&1X3MV7;[:2B C;CN-0(9)F66BMV
MQ4NJCWNJ0LCCLF$*=A'--$N_H4;F%:4/CG=)O2344Y,-1 2(<N.^3!16.7H#
M) B-W5[\2\?ZW&13\#(VZ@)43; _[O%'8HYJI\F0E%]%)2T/8/KV74N33=8
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M$-59/.#I_6>%MCQ%\3Q;YMK($SX#CIPY<F4:!\QJ  8<EV>"KN58! F"&7*
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M7[MNMX+A<NV^7RV@$^RV>CEZ 5!+ P04    " !N@&)6E*8IWX<)   *"@
M%    &%R9'@M,C R,S S,#)?9S$N:G!GG=5W5!-('@?PA"20(%D-36 I"H(A
M(+U&6 6D2XTD@"9+* I$$%!*L'" @(0N32-!Z4T2@:!T44HP-*D!7$6J2E&(
M]$4XW'?EG_OC[K[S9O[YS9LWGS?S9O;']C\"CEB969H!@#P  /"@ ?;? 4P
M4%Y>/EX(E(^/#P:#\@L(PP4.'1(0%Q0Z+"PE(2,M)2$I>>R$RLECLLIRDI)(
M745E-74M+2V9D_J&>AH&*II:&C\7 <)@,(%# F)PN)C&<<GC&O]S]EL!""B
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MBP<,!H'Y?KJ /*$_)R# D./JO()&#GS$0"%9C4BHL'%:7M4KF)RFXXJ(>]
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MN\KJ:W1Z2S<,-_$V<7SU00.!S7Q"<:WOS S<6R8KW9XA-)9V>@V5.'"(#+D
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M?D- !YJR5&)&T_96DLQ4NE#Z33?@X#4U43OXR4#[XW\'4$L#!!0    ( &Z
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M6K9">ZEX<Z)?S85,YU\*>9I?:=_CLC*_\^H[Q6>E9#&/D"0QBD( N>#:P*@
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M4$L! A0#%     @ ;H!B5@BX&O:W)   D'@! !P              ( !
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M>"TR,#(S,#,P,E]L86(N>&UL4$L! A0#%     @ ;H!B5F 02QC3!@  ]#(
M !4              ( !L5   &%R9'@M,C R,S S,#)?<')E+GAM;%!+!08
1    !@ & ) !  "W5P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
